Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing

著录项

• 来源
  《药学学报（英文版）》 |2021年第3期|694-707|共14页
• 作者

  Zhiru Wang; Hong-Min Liu; Wenting Kang; Ouwen Li; Fengyu Qi; Junwei Wang; Yinghua You; Pengxing He; Zhenhe Suo; Yichao Zheng;

  展开▼
• 作者单位

  School of Pharmaceutical Sciences Zhengzhou University;

  Co-Innovation Center of Henan Province for New Drug R&D and Preclinical Safety;

  State Key Laboratory of Esophageal Cancer Prevention and Treatment Key Laboratory of Advanced Drug Preparation Technologies Ministry of Education of China Zhengzhou 450001 China;

  Department of Pathology the Norwegian Radium Hospital Oslo University Hospital;

  department of Pathology Institute for Clinical Medicine Faculty of Medicine University of Oslo Oslo 0379 Norway;

  School of Pharmaceutical Sciences Zhengzhou University;

  Co-Innovation Center of Henan Province for New Drug R&D and Preclinical Safety;

  State Key Laboratory of Esophageal Cancer Prevention and Treatment Key Laboratory of Advanced Drug Preparation Technologies Ministry of Education of China Zhengzhou 450001 China;

  School of Pharmaceutical Sciences Zhengzhou University;

  Co-Innovation Center of Henan Province for New Drug R&D and Preclinical Safety;

  State Key Laboratory of Esophageal Cancer Prevention and Treatment Key Laboratory of Advanced Drug Preparation Technologies Ministry of Education of China Zhengzhou 450001 China;

  School of Pharmaceutical Sciences Zhengzhou University;

  Co-Innovation Center of Henan Province for New Drug R&D and Preclinical Safety;

  State Key Laboratory of Esophageal Cancer Prevention and Treatment Key Laboratory of Advanced Drug Preparation Technologies Ministry of Education of China Zhengzhou 450001 China;

  School of Pharmaceutical Sciences Zhengzhou University;

  Co-Innovation Center of Henan Province for New Drug R&D and Preclinical Safety;

  State Key Laboratory of Esophageal Cancer Prevention and Treatment Key Laboratory of Advanced Drug Preparation Technologies Ministry of Education of China Zhengzhou 450001 China;

  School of Pharmaceutical Sciences Zhengzhou University;

  Co-Innovation Center of Henan Province for New Drug R&D and Preclinical Safety;

  State Key Laboratory of Esophageal Cancer Prevention and Treatment Key Laboratory of Advanced Drug Preparation Technologies Ministry of Education of China Zhengzhou 450001 China;

  School of Pharmaceutical Sciences Zhengzhou University;

  Co-Innovation Center of Henan Province for New Drug R&D and Preclinical Safety;

  State Key Laboratory of Esophageal Cancer Prevention and Treatment Key Laboratory of Advanced Drug Preparation Technologies Ministry of Education of China Zhengzhou 450001 China;

  School of Pharmaceutical Sciences Zhengzhou University;

  Co-Innovation Center of Henan Province for New Drug R&D and Preclinical Safety;

  State Key Laboratory of Esophageal Cancer Prevention and Treatment Key Laboratory of Advanced Drug Preparation Technologies Ministry of Education of China Zhengzhou 450001 China;

  Department of Pathology the Norwegian Radium Hospital Oslo University Hospital;

  department of Pathology Institute for Clinical Medicine Faculty of Medicine University of Oslo Oslo 0379 Norway;

  School of Pharmaceutical Sciences Zhengzhou University;

  Co-Innovation Center of Henan Province for New Drug R&D and Preclinical Safety;

  State Key Laboratory of Esophageal Cancer Prevention and Treatment Key Laboratory of Advanced Drug Preparation Technologies Ministry of Education of China Zhengzhou 450001 China;

  展开▼
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词